Braveheart Bio director granted 30,000 stock options
Braveheart Bio, Inc. director Lohoff Tim reported a grant of stock options on August 5, 2026.
Rhea-AI Filing Summary
Braveheart Bio, Inc. director Lohoff Tim reported a grant of stock options on August 5, 2026. The award covers 30,000 Stock Options (Right to Buy) with an exercise price of $18.00 per share, expiring on August 4, 2036. These options, representing 30,000 underlying common shares, were acquired at a grant price of $0.00 and are held as direct ownership. According to the award terms, all shares underlying the option will vest in full on the earlier of August 5, 2027 or the date of the issuer's next annual stockholder meeting, conditioned on the reporting person's continued service to the company through that vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 30,000 shares
Grant/Award
1 txn
Insider
Lohoff Tim
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 30,000 contracts (Direct)
Footnotes (1)
- F1. The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Key Figures
Options Granted: 30,000 shares
Exercise Price: $18.00 per share
Expiration Date: August 4, 2036
+3 more
6 metrics
Options Granted
30,000 shares
Stock Option (Right to Buy) grant to director on August 5, 2026
Exercise Price
$18.00 per share
Conversion or exercise price of granted stock options
Expiration Date
August 4, 2036
Expiration of stock options granted to director
Underlying Shares
30,000 shares
Common stock underlying the granted stock options
Vesting Date
August 5, 2027
Latest possible full vesting date, subject to earlier annual meeting and continued service
Post-transaction Derivative Holdings
30,000 options
Total stock options held following the reported grant
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion or exercise price of 18.0000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares underlying the stock option will vest in full upon the earlier"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-08-04"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
derivative securities financial
"transaction_type: derivative"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Braveheart Bio (BRVE) director Tim Lohoff report in this Form 4?
Tim Lohoff reported a grant of 30,000 stock options to buy Braveheart Bio common stock. The award was granted at $18.00 per share and expires on August 4, 2036, with vesting tied to future service.
How many Braveheart Bio (BRVE) options did Tim Lohoff receive and at what price?
Tim Lohoff received 30,000 stock options for Braveheart Bio, each with an exercise price of $18.00 per share. These options give him the right to buy an equal number of common shares if exercised before expiration.
When do Tim Lohoff’s Braveheart Bio (BRVE) stock options vest?
The options will vest in full on the earlier of August 5, 2027 or the date of Braveheart Bio’s next annual stockholder meeting, provided Tim Lohoff continues serving the company through that vesting date.
What is the expiration date of the Braveheart Bio (BRVE) options granted to Tim Lohoff?
The granted options expire on August 4, 2036. After that date, any unexercised options will lapse, meaning they can no longer be used to purchase Braveheart Bio common stock at the $18.00 exercise price.
Is the Form 4 transaction for Braveheart Bio (BRVE) a purchase or a grant?
The Form 4 reports a grant/award acquisition of stock options, coded “A,” rather than an open-market purchase or sale. The options were acquired at a grant price of $0.00, with value realized only if later exercised above $18.00.
AI-generated analysis. How Rhea-AI works. Not financial advice.
